Immunology Core (Basic Science Core)
Immunology Core (Basic Science Core)
批准号:
10673776
负责人:
GEORGIA Doris TOMARAS
金额:
$15.15万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
未结题
起止时间:
2005-04-01 至 2025-06-30
关键词:
Acquired Immunodeficiency SyndromeAddressAlgorithmsAntibodiesAntigen-Antibody ComplexAreaAvidityAwardB cell repertoireB-LymphocytesBasic ScienceBindingBiological AssayCell SeparationCellsCellular AssayCellular ImmunologyChargeClinicalCollaborationsCommunitiesComplement ActivationConsultationsCore FacilityCountryDataData AnalysesDetectionDevelopmentDrug KineticsEducationEducational workshopEffector CellEnsureEpidemicEpitope MappingEquityFc ReceptorFlow CytometryFosteringGene Expression ProfilingGoalsHIVHIV InfectionsHIV Vaccine Trials NetworkHIV-1HIV/AIDSHumanImmuneImmunogenomicsImmunologic MonitoringImmunologicsImmunologyImmunology procedureInfectionInstitutionInternationalInternational Maternal Pediatric Adolescent AIDS Clinical TrialsInvestmentsLaboratoriesLeadMalariaMeasurementMediatingMental HealthMentorsMentorshipMethodologyMethodsMicroscopyMissionMonitoring Clinical TrialsMonoclonal AntibodiesMucous MembraneOrganPerformancePharmaceutical PreparationsPhasePhenotypePoliciesPreventionProphylactic treatmentPublicationsQuality ControlRecording of previous eventsResearchResearch PersonnelResearch PriorityResearch TrainingResource-limited settingScienceScientistServicesSpecificityStandardizationSubstance abuse problemSystemT-LymphocyteTechnologyTrainingTranslatingTyphoid FeverUnited States National Institutes of HealthVaccinationVaccine DesignVaccinesVirionVirusWorkantibody testassay developmentcareer developmentco-infectioncomorbiditydata integrityfluhealth disparityinnovationmonocyteneutralizing antibodyneutrophilnovelprotein structurequality assurancereceptor bindingresponsestructural biologytoolvaccine evaluationvirology
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY – Immunology Core (Basic Science Core)
The overall goal of the Immunology Core is to provide Duke HIV/AIDS scientists, clinicians, collaborators, and
trainees access to an innovative, state-of-the-art, and standardized repertoire of immunologic assays that can
comprehensively and deeply interrogate the immunologic space in response to HIV-1 infection, vaccination,
co-infections, and cure strategies. The Immunology Core will continue to address gaps in the field. Three key
examples of accomplishments to date are the following: 1) Provided implementation and training of
standardized neutralization, binding, and cellular assays to national and international laboratories, such that
diverse studies across multiple laboratories can now be directly and rigorously compared for advancing the
science to the next phase. 2) Fostered innovation of new assay development and analysis for multiple
simultaneous measurements, significantly advancing the depth and breadth of immunological information (i.e.
global virus panels for neutralization breadth, immune monitoring assays for TB, flu, malaria, and typhoid, PK
and functional ADA assays for broadly neutralizing antibodies, comprehensive array of Fc effector function
assays, Env characterization on infected cells, novel analytical algorithms, and training for flow cytometric
analyses (such as FLowPET) to integrate complex immunological data and multiplex binding breadth assays.
3) Provided scientific training and mentoring to Duke young investigators, resulting in R01 and P01 awards,
high-impact publications, and career development opportunities. 4) Implemented a recharge system to
provide services to the CFAR community. Thus, the Immunology Core investigators have a strong history
together and are uniquely poised to tackle newly emerging gaps in the field of HIV-1 immunology. The Duke
CFAR’s priority areas for innovative research at Duke are supported by the science and technology offered by
the Immunology Core: 1) the ‘Southern HIV Epidemic’, 2) HIV Co-Morbidities and Co-Infections, 3) Latency
and Eradication, 4) Health Disparities, 5) Vaccine Design and Evaluation, 6) Mental Health and Substance
Abuse, 7) the HIV Organ Policy Equity (HOPE) Act, and 8) Emerging Infections. The Immunology Core’s
assay platform and commitment to innovation is ideally suited for support of the Duke CFAR priority areas
and Specific Aims, as well as broadly covering the current and emerging needs of the Duke CFAR community
of scientists and clinicians. As part of the overall Duke CFAR Aims, the Core will provide advanced assays
and technologies to CFAR investigators, provide support and training for early stage investigators, and
support NIH initiatives (PAVEG, HVTN, IMPAACT, HPTN, CHAVI-ID/CHAVD, MIG, CURE, EQAPOL) and
collaborative partnerships with other CFARs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Impact of Antibody Effector Function Diversity on Antiviral Activity In Situ
-
批准号:10258146
-
项目类别:
-
资助金额:$434.33万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Mechanisms of Antibody Fc Mediated Protection
-
批准号:10475284
-
项目类别:
-
资助金额:$59.14万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Administrative Core
-
批准号:10670243
-
项目类别:
-
资助金额:$25.9万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Antiviral Activity In Situ
-
批准号:10475294
-
项目类别:
-
资助金额:$85.28万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Impact of Antibody Effector Function Diversity on Antiviral Activity In Situ
-
批准号:10670229
-
项目类别:
-
资助金额:$444.84万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Administrative Core
-
批准号:10258147
-
项目类别:
-
资助金额:$33.21万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Impact of Antibody Effector Function Diversity on Antiviral Activity In Situ
-
批准号:10475274
-
项目类别:
-
资助金额:$426.07万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Antiviral Activity In Situ
-
批准号:10670262
-
项目类别:
-
资助金额:$59.14万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Mechanisms of Antibody Fc Mediated Protection
-
批准号:10258150
-
项目类别:
-
资助金额:$60.67万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Structure-Function Analytics Core
-
批准号:10670249
-
项目类别:
-
资助金额:$100.92万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Structure-Function Analytics Core
-
批准号:10258149
-
项目类别:
-
资助金额:$76.49万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Mechanisms of Antibody Fc Mediated Protection
-
批准号:10670254
-
项目类别:
-
资助金额:$85.63万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Structure-Function Analytics Core
-
批准号:10475280
-
项目类别:
-
资助金额:$73.44万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Administrative Core
-
批准号:10475275
-
项目类别:
-
资助金额:$30.2万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Antiviral Activity In Situ
-
批准号:10258152
-
项目类别:
-
资助金额:$100.02万
-
财政年份:2021
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Bridging Antibody Fc-mediated Antiviral Functions Across Humans and Non-human Primates
-
批准号:9925737
-
项目类别:
-
资助金额:$410.48万
-
财政年份:2016
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Administrative Core
-
批准号:9140248
-
项目类别:
-
资助金额:$14.72万
-
财政年份:2016
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Bridging Antibody Fc-mediated Antiviral Functions Across Humans and Non-human Primates
-
批准号:9140247
-
项目类别:
-
资助金额:$326.41万
-
财政年份:2016
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Centers for AIDS Research (CFAR)
-
批准号:10163778
-
项目类别:
-
资助金额:$330.19万
-
财政年份:2005
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
Evaluating the use of long-acting antiretroviral treatment for HIV during community re-entry: Addressing community and structural barriers
-
批准号:10818986
-
项目类别:
-
资助金额:$50.67万
-
财政年份:2005
-
负责人:GEORGIA Doris TOMARAS
-
依托单位:
海外基金